secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zentalis Pharmaceuticals, Inc. (ZNTL)
CIK:        0001725160
Form:       8-K
Filed at:   2025-12-15T23:59:59+00:00
Accession:  0001725160-25-000164
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.01, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Zentalis repurchases 7.5M shares from Matrix at $1.33 each; director resigns
----------------------------------------------------------------------------

- Repurchased 7,500,000 shares from Matrix Capital Master Fund at $1.33/share, a 5% discount to the Dec 12 close of $1.40.
- Repurchase closed on December 15, 2025; funded by existing cash, with no material impact on projected cash runway into late 2027.
- Director Karan Takhar (Matrix Capital) resigned immediately, reducing board size from 7 to 6; resignation not due to any disagreement.
- Matrix's sale is part of its previously announced 2024 plan to wind down its family of funds.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1725160/000172516025000164/0001725160-25-000164-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1725160/000172516025000164/zntl-20251215.htm
  HTML page:      https://secwatch.observer/filing/0001725160-25-000164

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer